AstraZeneca is expected to release the highly anticipated results of the third phase of vaccine trials in the coming weeks.
At the same time, the demand for the company's drugs remained high, despite the disruptions in the work of health systems due to the pandemic.
According to the results of the financial report, the company's sales grew by 7% in the quarter ended September 30, and reached $ 6.52 billion. Revenues from co-developed drugs and currency fluctuations were not included in the calculation.
Basic earnings per share were 94 cents per share against the forecast of 98 cents.
At the end of the year, AstraZeneca expects to increase total revenue by 7-13% and increase basic earnings per share by 14-19%.
